Deutsche Bank upgrades DVA from Hold to Buy

The Rating Action

Deutsche Bank upgraded DaVita Inc. (DVA) from Hold to Buy on 2026-05-06. The $12.8B market cap medical care facilities stock closed at $193.88 per share ahead of the rating announcement, following a 23.46% intraday gain on May 5.

Consensus Coverage Context

As of May 1, 2026, the broad analyst consensus for DVA was heavily weighted to Hold ratings, with just 1 Buy rating, 6 Hold ratings, and 1 Strong Sell rating across 8 total covered analysts. Prior months showed slight variation: in February 2026, the consensus included 1 Strong Buy, 1 Buy, 7 Hold, and 1 Strong Sell rating. Deutsche Bank’s upgrade shifts the firm’s stance from the prevailing hold-heavy consensus, joining the single existing Buy rating to push the aggregate Buy share to 2 out of 8 analysts.

Fundamental & Insider Cross-Reference

The rating announcement follows two key May 5, 2026 disclosures: DaVita’s Q1 2026 earnings beat and a Form 4 insider transaction filing. DaVita posted EPS of $2.87, beating consensus estimates of $2.33, and revenue of $3.415B, surpassing the $3.356B consensus forecast. On the same day, Berkshire Hathaway Inc.—a 10% owner of DVA—sold 1,220,376 shares at $149.8429 per share, totaling $182,864,679, per the SEC Form 4 filing. The company also released its Q1 10-Q and an 8-K regulatory update on May 5.

Unsignaled Context

This rating action does not include three critical unstated details: first, it does not disclose a formal price target, as none was referenced in the provided rating change data. Second, it does not reflect the May 5 Berkshire Hathaway share sale, as the rating announcement was issued the following trading day. Third, it does not incorporate post-December 2025 institutional holding shifts: the most recent 13F filing (as of 2025-12-31) shows a net 37 decline in institutional holders from the prior period, with total institutional ownership of 77% of DVA’s float, but no updated 13F data for May 2026 is available.